Paper Details

  1. Home
  2. Paper Details

Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

Author: BookerS V, CelanoP, GiardielloF M, HamiltonS R, HylindL M, KrushA J, OfferhausG J, PiantadosiS, RobinsonC R

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Sulindac, a nonsteroidal anti-inflammatory drug, has shown promise in reducing the number of polyps in patients with familial adenomatous polyposis (FAP), a disorder characterized by the development of numerous colorectal polyps. However, no controlled trials have been conducted in FAP patients who haven't undergone surgery.
Paper Details　
Original Abstract of the Article :
Familial adenomatous polyposis is an autosomal dominant disorder characterized by the formation of hundreds of colorectal adenomas and eventual colorectal cancer. Administration of the nonsteroidal antiinflammatory drug sulindac has been followed by regression of polyps in patients with this disorde...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM199305063281805

データ提供：米国国立医学図書館（NLM）

Treating Colonic and Rectal Adenomas with Sulindac

Familial adenomatous polyposis (FAP), a genetic disorder characterized by the formation of numerous polyps in the colon and rectum, can be a daunting challenge, like navigating a desert landscape riddled with treacherous obstacles. This research explores the potential of sulindac, a nonsteroidal anti-inflammatory drug, to treat colonic and rectal adenomas in patients with FAP.

The study investigates the efficacy of sulindac in treating colonic and rectal adenomas in patients with FAP, exploring its potential to prevent the development of colorectal cancer. The researchers aimed to evaluate the drug's effectiveness in a controlled trial setting, offering valuable data for clinicians and patients.

The study suggests that sulindac may be effective in reducing the number and size of polyps in patients with FAP, offering a potential therapeutic strategy for managing this condition. The findings provide evidence of sulindac's ability to induce polyp regression and potentially reduce the risk of colorectal cancer development.

Managing FAP with Sulindac

The research highlights the potential of sulindac as a valuable therapeutic option for patients with FAP. The study's findings suggest that sulindac can induce polyp regression and may play a role in preventing colorectal cancer development.

New Hope for FAP Patients

This research offers a glimmer of hope for patients with FAP, suggesting that sulindac may be an effective treatment option for managing this condition and reducing the risk of colorectal cancer.

Dr.Camel's Conclusion

In the fight against FAP, scientists are constantly seeking new ways to tame the desert landscape of polyps. This research suggests that sulindac may be a valuable tool for managing this condition and preventing the development of colorectal cancer.

Date :
  1. Date Completed 1993-05-11
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

8385741

DOI: Digital Object Identifier

10.1056/NEJM199305063281805

Related Literature

Article Analysis
・Side Effects of sulindac
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.